- Home
- MPLX vs EW Comparison
MPLX vs EW Comparison
Compare MPLX & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPLX
- EW
- Stock Information
- Founded
- MPLX 2012
- EW 1958
- Country
- MPLX United States
- EW United States
- Employees
- MPLX N/A
- EW N/A
- Industry
- MPLX Oil & Gas Production
- EW Industrial Specialties
- Sector
- MPLX Energy
- EW Health Care
- Exchange
- MPLX Nasdaq
- EW Nasdaq
- Market Cap
- MPLX 49.9B
- EW 42.5B
- IPO Year
- MPLX 2012
- EW 2000
- Fundamental
- Price
- MPLX $47.26
- EW $74.78
- Analyst Decision
- MPLX Buy
- EW Buy
- Analyst Count
- MPLX 11
- EW 21
- Target Price
- MPLX $48.82
- EW $79.40
- AVG Volume (30 Days)
- MPLX 2.0M
- EW 5.6M
- Earning Date
- MPLX 02-04-2025
- EW 02-04-2025
- Dividend Yield
- MPLX 8.10%
- EW N/A
- EPS Growth
- MPLX 21.97
- EW 193.69
- EPS
- MPLX 4.24
- EW 6.89
- Revenue
- MPLX $11,043,000,000.00
- EW $6,314,900,000.00
- Revenue This Year
- MPLX $14.01
- EW N/A
- Revenue Next Year
- MPLX $4.95
- EW $0.91
- P/E Ratio
- MPLX $11.15
- EW $28.85
- Revenue Growth
- MPLX 6.20
- EW 24.02
- 52 Week Low
- MPLX $36.28
- EW $58.93
- 52 Week High
- MPLX $51.94
- EW $96.12
- Technical
- Relative Strength Index (RSI)
- MPLX 46.57
- EW 62.35
- Support Level
- MPLX $45.89
- EW $72.29
- Resistance Level
- MPLX $49.33
- EW $74.58
- Average True Range (ATR)
- MPLX 1.05
- EW 1.93
- MACD
- MPLX -0.45
- EW 0.06
- Stochastic Oscillator
- MPLX 25.23
- EW 91.36
About MPLX MPLX LP
MPLX is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in 2019.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.